Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chromium Cr-51 is a synthetic radioactive isotope of the element chromium, with a half-life of approximately 27.7 days. It decays by electron capture, emitting gamma rays (0.32 MeV). Chromium Cr-51 is primarily used as a diagnostic radiopharmaceutical agent in medicine and research. In clinical practice, it is used to label red blood cells for measuring their mass or volume, studying red blood cell survival time and sequestration, evaluating blood loss, diagnosing gastrointestinal bleeding, and labeling platelets for survival studies. In nephrology, it helps determine glomerular filtration rate. Chromium Cr-51 is also widely used in laboratory assays such as cytotoxicity studies (chromium release assays) to quantify immune cell-mediated lysis of target cells[1][2][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chromium Cr-51.